Patent ID: 9694081
Date: 2017-07-04
CPC Classifications: A61K

Claim:
1. A process for delivery of an inhibitor of matrix metalloprotease to the extracellular matrix of targeted tissue comprising: administering a hydrogel composition to a patient; said hydrogel composition comprising: biocompatible hydrogel, said hydrogel comprising a plurality of cross-linkers connecting backbone components of said hydrogel; and a therapeutic agent comprising an inhibitor of matrix metalloprotease encapsulated within said hydrogel; wherein said hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by a matrix metalloprotease; said inhibitor being effective as a treatment of a condition related to the presence of said matrix metalloprotease; wherein said hydrogel contains binding groups to said inhibitor of matrix metalloprotease to retain the inhibitor within the intact hydrogel; allowing said hydrogel composition to contact matrix metalloprotease in said extracellular matrix of targeted tissue; said contact resulting in the release of at least a portion of said inhibitor of matrix metalloprotease.